Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCKBR | P32239 | 9/20 | 0.41 |
| ▸ | CCKAR | P32238 | 7/20 | 0.41 |
| ▸ | OPRD1 | P41143 | 8/20 | 0.40 |
| ▸ | OPRM1 | P35372 | 4/20 | 0.40 |
| ▸ | OPRK1 | P41145 | 4/20 | 0.40 |
| ▸ | PSEN1 | P49768 | 4/20 | 0.39 |
| ▸ | PSEN2 | P49810 | 4/20 | 0.39 |
| ▸ | APH1B | Q8WW43 | 4/20 | 0.39 |
| ▸ | NCSTN | Q92542 | 4/20 | 0.39 |
| ▸ | APH1A | Q96BI3 | 4/20 | 0.39 |
| ▸ | PSENEN | Q9NZ42 | 4/20 | 0.39 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.38 |
| ▸ | AMY2A | P04746 | 2/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31247969 | 0.97 | ABCB1 (0.40) | CCKBRCCKAROPRD1OPRM1OPRK1 | |
| SCHEMBL31247896 | 0.96 | PSEN1 (0.40) | CCKBRCCKAROPRD1OPRM1OPRK1 | |
| SCHEMBL31247966 | 0.95 | OPRM1 (0.40) | CCKBRCCKAROPRD1OPRM1OPRK1 | |
| SCHEMBL31247960 | 0.95 | OPRD1 (0.40) | CCKBRCCKAROPRD1OPRM1OPRK1 | |
| SCHEMBL38652065 | 0.92 | PSEN1 (0.43) | CCKBRCCKAROPRD1OPRM1OPRK1 | |
| SCHEMBL30892072 | 0.92 | PSEN1 (0.42) | OPRD1OPRM1OPRK1PSEN1PSEN2 | |
| SCHEMBL30930720 | 0.92 | ACE (0.42) | CCKBRCCKARPSEN1PSEN2APH1B | |
| SCHEMBL31501260 | 0.91 | ABCB1 (0.41) | CCKBRCCKAROPRD1OPRM1OPRK1 | |
| SCHEMBL31522801 | 0.91 | ABCB1 (0.39) | CCKBRCCKAROPRD1ABCB1AMY2A | |
| SCHEMBL31522796 | 0.90 | PSMB1 (0.38) | CCKBRCCKARPSEN1PSEN2APH1B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-119874492-A | Novel method for synthesizing teicoplanin fragment | 九洲药业(杭州)有限公司 | 2025-04-25 | — | — | CN | disclosed |
| US-20240424063-A1 | LONG ACTING GLP-1/GIP DUAL AGONISTS | SUN PHARMACEUTICAL IND LTD (IN) | 2024-12-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240424063-A1 | LONG ACTING GLP-1/GIP DUAL AGONISTS | GLP1R, GIPR, GPR119 | CCKBR 42/4885CCKAR 34/4885OPRD1 923/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.